Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.

Endpoints NewsFDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering

CellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation

CellA blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers

CellA cell type-specific mechanism driving the rapid antidepressant effects of transcranial magnetic stimulation

FierceBiotechAnalysts cut enGene cancer sales forecast after updated data widen gap to J&J

BioPharma DiveFDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended

10x Genomics News10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up - Zacks Investment Research

Eli LillyWill Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - The Motley Fool

AbbottAbbott's Medical Device Strategy Supports Long-Term Growth Outlook - The Globe and Mail

FDA News ReleasesFDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics

BioPharma DiveLilly, Gilead lead pharma’s M&A boom

Endpoints News'Pharma, not really’: Top young AI talent shuns careers at big drugmakers